Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIO-RAD LABORATORIES, INC. Director's Dealing 2021

Sep 8, 2021

30786_dirs_2021-09-08_9bffc370-7fae-4298-aaad-4406a255abb2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-RAD LABORATORIES, INC. (BIO BIOB)
CIK: 0000012208
Period of Report: 2021-09-03

Reporting Person: SCHWARTZ NORMAN D (Director, Chairman, President, and CEO, 10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-09-03 Bio-Rad A Common Stock M 2319 $.00 Acquired 422200 Direct
2021-09-03 Bio-Rad A Common Stock F 1150 $819.70 Disposed 421050 Direct
2021-09-04 Bio-Rad A Common Stock M 2600 $.00 Acquired 423650 Direct
2021-09-04 Bio-Rad A Common Stock F 1290 $819.70 Disposed 422360 Direct
2021-09-05 Bio-Rad A Common Stock M 2600 $.00 Acquired 424960 Direct
2021-09-05 Bio-Rad A Common Stock F 1290 $819.70 Disposed 423670 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-09-03 Restricted Stock Units $0 M 2319 Disposed Bio-Rad A Common Stock (2319) Direct
2021-09-04 Restricted Stock Units $0 M 2600 Disposed Bio-Rad A Common Stock (2600) Direct
2021-09-05 Restricted Stock Units $0 M 2600 Disposed Bio-Rad A Common Stock (2600) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Bio-Rad B Common Stock 12838 Indirect
Bio-Rad B Common Stock 4060054 Indirect
Bio-Rad B Common Stock 298274 Direct

Footnotes

F1: Shares of Class A common stock acquired on the vesting of restricted stock units.

F2: The reporting person disclaims beneficial ownership of these shares.

F3: The shares are held by a limited partnership of which the reporting person is a limited and general partner. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F4: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

F5: On September 3, 2019, the reporting person was granted 11,597 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.

F6: On September 4, 2018, the reporting person was granted 13,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.

F7: On September 5, 2017, the reporting person was granted 13,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.